Advanced Endometrial Cancer, Cervical Cancer and Ovarian Cancer
Conditions
Brief summary
This is a study to evaluate the efficacy and safety of TQ-B3525 in subjects with recurrent / metastatic advanced endometrial cancer, cervical cancer and ovarian cancer with PIK3CA and / or PIK3R1 / 2 gene-altered (mutation or amplification). Endometrial cancer, cervical cancer and ovarian cancer are divided into three cohorts, each cohort administrated TQ-B3525 tablet orally once a day.
Interventions
DRUGTQ-B3525 tablet
TQ-B3525 tablet administered orally once a day. Each cycle is 28 days.
Sponsors
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
Study design
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT
Masking
NONE
Eligibility
Sex/Gender
FEMALE
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
* 1\. Pathologically confirmed malignant gynecological neoplasm. 2. Has PIK3CA and/or PIK3R1/2 Gene-altered. 3.Unresectable, locally advanced recurrent and/or metastatic tumors, has at least 1 measurable lesion. 4.Failed with standard treatment or has no effective treatment. 5. 18 years and older, Eastern Cooperative Oncology Group(ECOG) performance status score of 0 to 1, Life expectancy ≥ 3 months. 6\. Male or female subjects should agree to use an adequate method of contraception starting with the first dose of study therapy through 6 months after the last dose of study (such as intrauterine devices , contraceptives or condoms) ；No pregnant or breastfeeding women, and a negative pregnancy test are received within 7 days before the first administration. 7.Understood and signed an informed consent form.
Exclusion criteria
* 1.Has untreated or active central nervous system metastases. 2.Has diagnosed and/or treated additional malignancy within 3 years prior to the first administration. 3\. Insufficient hematopoietic function of bone marrow. 4. Dysfunction of liver and kidney. 5. Bleeding risk. 6. Dysfunction of gastrointestinal tract. 7.Dysfunction of heart and cerebral vessels. 8.Has received PI3K, AKT, mTOR inhibitor. 9.Has participated in other clinical trails within 30 days. 10. Has received surgery, or unhealed wounds within 4 weeks before the first administration. 11\. Has received organ grafting, or hematopoietic stem cell transplantation within 60 days before the first administration, or host versus graft reaction. 12\. The patients required immunosuppressor, or the whole-body, or absorbable local hormone therapy for immunosuppression purposes and continued to use within 7 days before the initial administration (daily dose of glucocorticoid \<10 mg, except metacortandracin or other therapeutic hormones and so on). 13\. Has active infections. 14. Has human immunodeficiency virus (HIV). 15. Pregnant or lactating women. 16. Has psychotropic substances abuse or a mental disorder. 17. Has other conditions that make it inappropriate for the patient to be enrolled based on investigator's opinion. 18\. Patient's compliance is inadequate.
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Overall response rate (ORR) assessed by Independent Review Committee | up to 48 weeks | Percentage of participants achieving complete response (CR) and partial response (PR) based on IRC. |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Disease control rate（DCR） | up to 48 weeks | Percentage of subjects achieving complete response (CR) and partial response (PR) and stable disease (SD). |
| Duration of disease remission (DOR) | up to 48 weeks | The time from the first evaluation of the subject as CR or PR to the first evaluation of the subject as PD or death (whichever occurs first). |
| Overall response rate (ORR) assessed by Investigator | up to 48 weeks | Percentage of participants achieving complete response (CR) and partial response (PR) assessed by investigator. |
| Overall survival (OS) | up to 72 weeks | OS defined as the time from the first dose to death from any cause. Survival time was censored at the date of last contact for patients who were still alive or lost to follow-up. |
| DOR rate (≥ 6 months) (percentage of subjects with disease remission duration ≥ 6 months) | up to 48 weeks | The percentage of subjects achieving CR or PR was recorded for the first time to 6 months after the first time of objective tumor progression or death due to any cause (whichever occurred first) was recorded. |
| Progression-free survival (PFS) | up to 48 weeks | PFS was defined as the time from the date of study enrollment to the date of the first of the following events, objective disease progression or death due to any cause. |
Countries
China
Outcome results
None listed